-
Mashup Score: 0
CHARLOTTE, N.C. — Exposure to ustekinumab and vedolizumab during pregnancy did not increase maternal and fetal complications, and researchers recommend continued use in pregnant mothers with inflammatory bowel disease. “There is some conflicting data regarding the safety of vedolizumab and ustekinumab in pregnancy,” Rishika Chugh, MD, assistant professor of medicine at the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0
CHARLOTTE, N.C. — Exposure to ustekinumab and vedolizumab during pregnancy did not increase maternal and fetal complications, and researchers recommend continued use in pregnant mothers with inflammatory bowel disease. “There is some conflicting data regarding the safety of vedolizumab and ustekinumab in pregnancy,” Rishika Chugh, MD, assistant professor of medicine at the
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Exposure to #ustekinumab and #vedolizumab during pregnancy did not increase maternal and fetal complications, and researchers recommend continued use in pregnant mothers with #IBD @RishikaChughMD #GITwitter #MedTwitter #ACG2022 https://t.co/WHGbnQMx9y
-
-
Mashup Score: 0VIDEO: ‘No difference’ between ustekinumab, tofacitinib for steroid-free remission in UC - 2 year(s) ago
CHARLOTTE, N.C. — In a Healio video exclusive, Rahul Dalal, MD, MPH, reported ustekinumab and tofacitinib yielded similar safety and efficacy in the treatment of a small subset of adult patients with ulcerative colitis. Specifically, among 97 patients who received ustekinumab (Stelara, Janssen) and 69 patients who received tofacitinib (Xeljanz, Pfizer), 48.9% and 56.1% achieved steroid-free
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from #ACG2022: @RahulSDalalMD reported ‘no difference’ between #ustekinumab, #tofacitinib for steroid-free remission in #UC #IBD @AmCollegeGastro #GITwitter #MedTwitter https://t.co/sG3tpq9U70
-
-
Mashup Score: 1VIDEO: ‘No difference’ between ustekinumab, tofacitinib for steroid-free remission in UC - 2 year(s) ago
CHARLOTTE, N.C. — In a Healio video exclusive, Rahul Dalal, MD, MPH, reported ustekinumab and tofacitinib yielded similar safety and efficacy in the treatment of a small subset of adult patients with ulcerative colitis. Specifically, among 97 patients who received ustekinumab (Stelara, Janssen) and 69 patients who received tofacitinib (Xeljanz, Pfizer), 48.9% and 56.1% achieved steroid-free
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
In a @GoHealio #GI video exclusive, @RahulSDalalMD reported #ustekinumab and #tofacitinib yielded similar safety and efficacy in the treatment of a small subset of adult patients with #ulcerativecolitis #UC #IBD #ACG2022 @AmCollegeGastro #GITwitter https://t.co/sG3tpq9U70
-
-
Mashup Score: 2Ustekinumab Quickly, Effectively Treats Patients with Active PsA - 2 year(s) ago
In the prospective, non-interventional SUSTAIN study, patients with active psoriatic arthritis received ustekinumab for 3 years in routine clinical care.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Patients with active #PsoriaticArthritis who were treated with #ustekinumab for 3 years (160 weeks) reported rapid onset of effect, which was maintained throughout treatment. https://t.co/n6Gg9qqT7M
-
-
Mashup Score: 0Ustekinumab fails to show superiority to placebo in lupus - 2 year(s) ago
Ustekinumab failed to demonstrate superiority to placebo among patients with active systemic lupus erythematosus, according to phase-3 data published in Annals of the Rheumatic Diseases. “The efficacy and safety of ustekinumab in patients with active SLE was evaluated in a phase 2, randomized, placebo-controlled study,” Ronald F. van Vollenhoven, MD, PhD, of the department of
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: #Ustekinumab failed to demonstrate superiority to placebo among patients with active systemic #lupus erythematosus https://t.co/AVZ1gKm4lE
-
-
Mashup Score: 1
Patients with pediatric psoriatic arthritis will now have access to the first-in-class treatment option, ustekinumab.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Janssen announced the @US_FDA approval of #ustekinumab (STELARA) for the treatment of pediatric patients, aged 6 years and older, with active #PsoriaticArthritis. https://t.co/B6H2LTOCrY
-
-
Mashup Score: 1FDA approves ustekinumab for pediatric psoriatic arthritis - 2 year(s) ago
The FDA has approved ustekinumab for the treatment of children aged 6 years and older with active psoriatic arthritis, according to a Janssen press release.“We know active pediatric psoriatic arthritis is a challenging inflammatory disease given its rarity and that symptoms, such as swollen joints and skin lesions, can vary significantly in presentation and severity,” Terence Rooney,
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: The @US_FDA approved #ustekinumab for the treatment of children aged 6 years and older with active psoriatic #arthritis https://t.co/qrnmD2oiwa
-
-
Mashup Score: 0FDA approves ustekinumab for pediatric psoriatic arthritis - 2 year(s) ago
The FDA has approved ustekinumab for the treatment of children aged 6 years and older with active psoriatic arthritis, according to a Janssen press release.“We know active pediatric psoriatic arthritis is a challenging inflammatory disease given its rarity and that symptoms, such as swollen joints and skin lesions, can vary significantly in presentation and severity,” Terence Rooney,
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
The @US_FDA has approved #ustekinumab for the treatment of children aged 6 years and older with active psoriatic #arthritis https://t.co/rQDDuunRay
-
-
Mashup Score: 0
Patients with pediatric psoriatic arthritis will now have access to the first-in-class treatment option, ustekinumab.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Patients with pediatric #PsoriaticArthritis will now have access to the first-in-class treatment option, #ustekinumab. https://t.co/G9XcwACbtp
-
#ICYMI: @RishikaChughMD reported #ustekinumab, #vedolizumab ‘seem perfectly safe’ during #pregnancy in #IBD patients #GITwitter #MedTwitter https://t.co/WHGbnR4GnG